The ability of androgens to inhibit apoptosis in both normal and malignant prostatic cells has been well documented. However, the underlying mechanisms are understood poorly. Here we demonstrated that forkhead transcription factor FKHR (FOXO1)-induced death of LNCaP cells was blocked by a synthetic androgen R1881. Androgen treatment also resulted in a reduction in transcriptional activity of FKHR in these cells. Moreover, treatment of LNCaP cells with R1881 led to a decrease in the intact FKHR protein (70 kDa) and an increase in a faster migrating protein band (60 kDa). Androgen-enhanced appearance of the 60-kDa protein was diminished specifically by lysosomal acidic cysteine protease inhibitors. Mass spectrometry analyses of the purified FLAG-tagged 70-and 60-kDa proteins demonstrated that the 60-kDa species is a FKHR protein product that lacks about 120 amino acid residues of the C-terminal end. Mutagenesis of the basic amino acid Arg 537 in the protease cleavage region, as suggested by mass spectrometry, abrogated both the androgen-induced accumulation of the 60-kDa product and decrease in cell death induced by FKHR, suggesting that the residue Arg 537 is a potential protease cleavage site. Finally, ectopic expression of the first 537 amino acids of FKHR produced an inhibitory effect on transcriptional activity of the intact protein. Together, these results suggest that androgens induce increased activity of an acidic cysteine protease, which in turn cleaves FKHR. This provides a mechanism by which androgens protect prostate cancer cells from the killing effect of FKHR.Androgens are critical for proliferation and apoptosis in both normal and malignant prostatic epithelial cell (1). Orchitectomy results in extensive apoptosis and involution of the rat ventral prostate and human prostate cancer xenografts (2-4). Regression of prostatic tumors in patients following androgen ablation therapy is associated with apoptotic death in malignant prostatic epithelium (5, 6). These findings suggest that androgens function as antiapoptotic factors in both normal and malignant prostatic cells.The tumor suppressor gene PTEN (phosphatase and tensin homolog deleted on chromosome ten; also known as MMAC1/ TEP1) is mutated frequently in a variety of tumors including prostate, brain, and endometrium (7-9). Although the overall prevalence of PTEN mutations in primary prostate cancer is low relative to other tumors (10), the gene product is lost frequently in advanced prostate tumors (11, 12). Inactivation of PTEN through different mechanisms such as deletion, methylation, or protein degradation has been implicated in progression of a number of tumors (7,8,(13)(14)(15)(16)(17). Heterozygous disruption results in hyperplasia of the prostate, skin, and colon. Prostate-specific homozygous deletion of PTEN alleles in mice results in metastatic prostate cancer (18). PTEN acts as a tumor suppressor protein primarily via its phosphatidylinositol phosphatase activity, which antagonizes the phosphatidylinositol 3-kinase/Akt pathway (19,20)....